Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic kidney disease · Advanced solid tumors

Bayer

Bayer AG

Bayer trial registry — 47 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE HQ
97,894 Employees
EMA registrant Type
Company details
Status
Public
HQ
Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE
Employees
97,894
Programs
47
Drugs
62
Patents
5
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Trials

Bayer clinical trials

Registry index of 47 ClinicalTrials.gov studies linked to Bayer programs — each row shows trial ID, program name, phase, status, and indication.

Bayer trial registry — 47 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Bayer.

  1. 22819 — Phase 1

    Clinical update

  2. 22723 — Phase 1

    Clinical update

  3. 22598 — Phase 1

    Clinical update

  4. 22342 — Phase 1

    Clinical update

  5. BAY 94-9027/21824 — Phase 3

    Clinical update

  6. 22665 — Phase 1

    Clinical update

  7. 22534 — Phase 1

    Clinical update

  8. 21948 — Phase 1

    Clinical update

Trial registry

47 studies
  15. 2023-507001-34-00

    14308

    Phase 2 active small_molecule

    Patients symptomatic with pulmonary hypertension associated with left ventricular systolic dysfunction (PH-sLVD)

    CTIS ↗
  22. 2023-508905-26-00

    22534

    Phase 1 active other

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    CTIS ↗
  23. 2023-509447-28-00

    22665

    Phase 1 active other

    Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack

    CTIS ↗
  24. 2023-509488-26-00

    22375

    Phase 1 active other

    Prevention of ischemic stroke in patients after an acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack in combination with antiplatelet therapy

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.